Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4184.00 +0.3% SILVER 57.27 +0.2% COPPER 6.57 +0.2% OIL 98.64 +0.7% PALLADIUM 1116.25 −1.1% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.650 +0.0% LIB 0.700 −2.8% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.770 +1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.54 −3.0% CASA 0.060 +0.0% DRY 0.220 +2.3% SOMA 0.570 +1.8% GOLD 4184.00 +0.3% SILVER 57.27 +0.2% COPPER 6.57 +0.2% OIL 98.64 +0.7% PALLADIUM 1116.25 −1.1% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.650 +0.0% LIB 0.700 −2.8% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.770 +1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.54 −3.0% CASA 0.060 +0.0% DRY 0.220 +2.3% SOMA 0.570 +1.8%
M&A / Property

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

By The Northwire Desk — AI Analysis Feb 18, 2026 · 17:30 BCT · 5.45 BRIACELL THERAPEUTICS CORP. J
BCT · Price

Executive Summary

  • BriaCell and its majority‑owned subsidiary BriaPro entered a definitive purchase agreement whereby BriaPro will acquire BriaCell’s exclusive worldwide license to develop and commercialize soluble CD80 (sCD80) as a cancer therapeutic.
  • As consideration, BriaPro will issue 23,972,589 common shares to BriaCell (≈ C$1.18 M), increasing BriaCell’s ownership in BriaPro to ~78%.
  • BriaPro will receive up to $3 million from BriaCell under a credit facility to fund R&D, and will pay UMBC 2% royalties on commercialization.

Key Details

  • Transaction Structure: License transfer of sCD80 technology plus related assets from BriaCell to BriaPro; BriaPro obtains worldwide development and commercial rights.
  • Share Consideration: 23,972,589 BriaPro common shares issued to BriaCell, valued at approximately C$1.18 million.
  • Post‑Transaction Ownership: BriaCell’s equity stake in BriaPro rises to roughly 78% after the share issuance.
  • Credit Facility: Up to US$3 million may be drawn by BriaPro from BriaCell for research and development; each draw requires BriaCell approval of fund use.
  • Royalty Obligation: BriaPro will pay UMBC a 2% royalty on net sales of any commercialized sCD80 product, plus other development cost reimbursements.
  • Closing Conditions: Anticipated closing around March 12 2026, subject to (i) approval by disinterested BriaPro shareholders and (ii) receipt of an independent third‑party valuation confirming fair market value.
  • Regulatory Compliance: Shareholder approval required under MI 61‑101; BriaCell’s own shares in BriaPro excluded from voting as an interested party.
  • Valuation Approach: BriaPro will rely on specified markets exemption for the formal valuation requirement but intends to obtain an independent valuation as a best‑practice measure.

Notable Quotes

“Our mission has been to develop safe and effective treatments for cancer patients who do not respond to existing treatments, and a transformational anti‑cancer agent such as sCD80 may provide us with such an additional opportunity,” said Dr. Bill Williams, President & CEO of BriaCell and BriaPro.

Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other